Form 4 for LH Labcorp
Accepted 2023-02-23 00:00:00 ET · period of report 2023-02-21 · accession 0001127602-23-006642 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-23 | 2023-02-21 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $250.58 | -8,000 | 9,069 | -47% | -$2.00M |
| D | 2023-02-23 | 2023-02-21 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | $182.51 | +3,000 | 17.1K | +21% | +$547.5K |
| D | 2023-02-23 | 2023-02-21 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | $0.00 | -3,000 | 4,300 | -41% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-21 | S | D | 8,000 | $250.58 | 9,069 | D | — | — | (F1) The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price. |
| 2 | Common | Common Stock | 2023-02-21 | M | A | 3,000 | $182.51 | 17,069 | D | — | — | |
| 3 | Derivative | Non-qualified Stock Options | 2023-02-21 | M | D | 3,000 | $0.00 | 4,300 | D | $182.51 · 2021-02-04 to 2030-02-03 | 3,000 Common Stock | (F2) Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. (F3) The option vested in three equal annual installments beginning on the date reflected in this column. |